MR Imaging Signs of Gadolinium Retention Are Not Associated with Long-Term Motor and Cognitive Outcomes in Multiple Sclerosis.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
06
09
2022
accepted:
04
02
2023
pmc-release:
01
04
2024
medline:
12
4
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
The long-term impact of gadolinium retention in the dentate nuclei of patients undergoing administration of seriate gadolinium-based contrast agents is still widely unexplored. The aim of this study was to evaluate the impact of gadolinium retention on motor and cognitive disability in patients with MS during long-term follow-up. In this retrospective study, clinical data were obtained from patients with MS followed in a single center from 2013 to 2022 at different time points. These included the Expanded Disability Status Scale score to evaluate motor impairment and the Brief International Cognitive Assessment for MS battery to investigate cognitive performances and their respective changes with time. The association with qualitative and quantitative MR imaging signs of gadolinium retention (namely, the presence of dentate nuclei T1-weighted hyperintensity and changes in longitudinal relaxation R1 maps, respectively) was probed using different General Linear Models and regression analyses. No significant differences in motor or cognitive symptoms emerged between patients showing dentate nuclei hyperintensity and those without visible changes on T1WIs ( Our findings suggest that gadolinium retention in the brains of patients with MS is not associated with long-term motor or cognitive outcomes.
Sections du résumé
BACKGROUND AND PURPOSE
The long-term impact of gadolinium retention in the dentate nuclei of patients undergoing administration of seriate gadolinium-based contrast agents is still widely unexplored. The aim of this study was to evaluate the impact of gadolinium retention on motor and cognitive disability in patients with MS during long-term follow-up.
MATERIALS AND METHODS
In this retrospective study, clinical data were obtained from patients with MS followed in a single center from 2013 to 2022 at different time points. These included the Expanded Disability Status Scale score to evaluate motor impairment and the Brief International Cognitive Assessment for MS battery to investigate cognitive performances and their respective changes with time. The association with qualitative and quantitative MR imaging signs of gadolinium retention (namely, the presence of dentate nuclei T1-weighted hyperintensity and changes in longitudinal relaxation R1 maps, respectively) was probed using different General Linear Models and regression analyses.
RESULTS
No significant differences in motor or cognitive symptoms emerged between patients showing dentate nuclei hyperintensity and those without visible changes on T1WIs (
CONCLUSIONS
Our findings suggest that gadolinium retention in the brains of patients with MS is not associated with long-term motor or cognitive outcomes.
Identifiants
pubmed: 36863844
pii: ajnr.A7807
doi: 10.3174/ajnr.A7807
pmc: PMC10084901
doi:
Substances chimiques
Gadolinium
AU0V1LM3JT
Contrast Media
0
Gadolinium DTPA
K2I13DR72L
Organometallic Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-402Informations de copyright
© 2023 by American Journal of Neuroradiology.
Références
Eur Radiol. 2022 Aug;32(8):5382-5391
pubmed: 35284989
Invest Radiol. 2015 Aug;50(8):473-80
pubmed: 26107651
PLoS One. 2015 Jun 01;10(6):e0126835
pubmed: 26030293
Radiology. 2021 Nov;301(2):409-416
pubmed: 34463554
Sci Rep. 2014 Aug 15;4:6085
pubmed: 25124526
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Neurol Sci. 2022 Apr;43(4):2631-2639
pubmed: 34735650
Neuroimage Clin. 2018;20:844-850
pubmed: 30278371
Radiology. 2014 Mar;270(3):834-41
pubmed: 24475844
Nat Rev Neurol. 2015 Oct;11(10):597-606
pubmed: 26369511
Cortex. 2010 Jul-Aug;46(7):858-68
pubmed: 19828143
J Magn Reson Imaging. 2019 Aug;50(2):445-455
pubmed: 30681245
BMC Neurosci. 2014 Jan 24;15:19
pubmed: 24456150
Brain Res Brain Res Rev. 2000 Mar;31(2-3):236-50
pubmed: 10719151
J Neuroradiol. 2020 Jun;47(4):250-258
pubmed: 32014494
BMC Neurol. 2012 Jul 16;12:55
pubmed: 22799620
AJNR Am J Neuroradiol. 2020 Jun;41(6):944-946
pubmed: 32381539
Lancet Neurol. 2021 Aug;20(8):653-670
pubmed: 34139157
JAMA. 2016 Jul 5;316(1):96-8
pubmed: 27380348
Brain Sci. 2021 Mar 09;11(3):
pubmed: 33803287
AJNR Am J Neuroradiol. 2017 Jul;38(7):1311-1316
pubmed: 28495943
Lancet Neurol. 2017 Jul;16(7):564-570
pubmed: 28653648
Eur Radiol. 2016 Dec;26(12):4577-4584
pubmed: 26905870
J Magn Reson Imaging. 2020 Jun;51(6):1912-1913
pubmed: 31664740
Invest Radiol. 2014 Oct;49(10):685-90
pubmed: 24872007
AJNR Am J Neuroradiol. 2019 Aug;40(8):1265-1273
pubmed: 31248867
J Neurol. 2018 Oct;265(10):2260-2266
pubmed: 30056570
J Neurophysiol. 1977 Sep;40(5):1214-24
pubmed: 409809
Neurology. 2007 Sep 18;69(12):1213-23
pubmed: 17875909
BMC Neurol. 2014 Sep 10;14:171
pubmed: 25204350
Neurology. 2019 Aug 6;93(6):e611-e623
pubmed: 31285398
PLoS One. 2015 Aug 18;10(8):e0134963
pubmed: 26284778
Invest Radiol. 2015 Jul;50(7):470-2
pubmed: 25756685
Neuroradiology. 2019 Feb;61(2):155-162
pubmed: 30617409
Hum Brain Mapp. 2012 Sep;33(9):2062-71
pubmed: 21882300